维里迪安治疗
VRDN
19.03
-0.53
-2.71%
维里迪安治疗
US · VRDN
#2731 按市值排名
上市于 1970
19.03
-0.53
-2.71%
实时 - 追踪5344个代码 - 心跳于376秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
增持
- 机构持股总比例上升了2.5个百分点。
机构持股
- 机构持股比例
- 119.61% +2.45pp
- 机构数量
- 266
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向分歧机构在上一报告期增持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向出现分歧。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund71.93%
Hedge Fund32.86%
VC/PE Fund8.77%
Public Company2.83%
Private Company1.45%
Sovereign Wealth Fund1.32%
Government Pension Fund0.31%
Insurance Company0.11%
主要股东 截至 2026-06-30
FMR
14.66% · 16.60M 股
BlackRock
7.55% · 8.55M 股
Bellevue Asset Management AG
5.94% · 6.73M 股
Paradigm Biocapital Advisors LP
5.93% · 6.72M 股
State Street Global Advisors
5.41% · 6.12M 股
T. Rowe Price Group, Inc.
5.07% · 5.75M 股
Point72 Asset Management, L.P.
5.02% · 5.69M 股
Vanguard Capital Management, LLC
4.62% · 5.23M 股
Fairmount Funds Management LLC
4.49% · 5.09M 股
Deep Track Capital, LP
3.17% · 3.59M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 38次买入 · 11次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Radhika Tripuraneni | Chief Medical Officer | 0.04% |
| Stephen Mahoney | Chief Executive Officer | 0.03% |
| Thomas Beetham | Chief Operating Officer | 0.01% |
| Seth Harmon | Senior VP of Finance and Accounting, Principal Financial & Accounting Officer | 0.01% |
| Arlene Morris | Independent Director | -- |
| Jeffrey Ajer | Director | -- |
| Tomas Kiselak | Independent Chairperson of Board | -- |
| Christopher Cain | Director | -- |
| Jennifer Moses | Independent Director | -- |
| Fairmount Funds Management LLC | -- | -- |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-08-18 | Jennifer Tousignant | Chief Legal Officer | Open Market Disposition | -4,212 | $24.50 |
| 2026-08-18 | Jennifer Tousignant | Chief Legal Officer | Derivative Exercise and Sale | -10,000 | $14.41–24.50 |
| 2026-08-13 | Radhika Tripuraneni | Chief Medical Officer | Derivative Exercise and Retained | +40,000 | $13.21 |
| 2026-06-30 | Arlene Morris | Independent Director | Other Derivative Acquisition | +32,341 | $18.48 |
| 2026-06-30 | Jeffrey Ajer | Director | Other Derivative Acquisition | +32,341 | $18.48 |
| 2026-06-30 | Tomas Kiselak | Independent Chairperson of Board | Other Derivative Acquisition | +32,341 | $18.48 |
| 2026-06-30 | Christopher Cain | Director | Other Derivative Acquisition | +32,341 | $18.48 |
| 2026-06-30 | Jennifer Moses | Independent Director | Other Derivative Acquisition | +32,341 | $18.48 |
| 2026-06-30 | Sarah Gheuens | Director | Other Derivative Acquisition | +32,341 | $18.48 |
| 2026-05-10 | Fairmount Funds Management LLC | -- | Open Market Acquisition | +1,176,470 | $17.00 |
| 2026-03-03 | Thomas Beetham | Chief Operating Officer | Intent to Sell (Form 144) | -3,048 | $30.19 |
| 2026-03-03 | Stephen Mahoney | Chief Executive Officer | Intent to Sell (Form 144) | -7,408 | $30.19 |
| 2026-03-03 | Seth Harmon | Senior VP of Finance and Accounting, Principal Financial & Accounting Officer | Intent to Sell (Form 144) | -2,031 | $30.19 |
| 2026-03-03 | Jennifer Tousignant | Chief Legal Officer | Intent to Sell (Form 144) | -1,675 | $30.19 |
| 2026-03-02 | Thomas Beetham | Chief Operating Officer | Sale to Issuer | -3,048 | $30.19 |
| 2026-03-02 | Thomas Beetham | Chief Operating Officer | Derivative Exercise and Retained | +9,409 | -- |
| 2026-03-02 | Stephen Mahoney | Chief Executive Officer | Sale to Issuer | -7,408 | $30.19 |
| 2026-03-02 | Stephen Mahoney | Chief Executive Officer | Derivative Exercise and Retained | +18,357 | -- |
| 2026-03-02 | Seth Harmon | Senior VP of Finance and Accounting, Principal Financial & Accounting Officer | Sale to Issuer | -2,031 | $30.19 |
| 2026-03-02 | Seth Harmon | Senior VP of Finance and Accounting, Principal Financial & Accounting Officer | Derivative Exercise and Retained | +6,267 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
维里迪安治疗 讨论区 0 条评论